Cyclerion Therapeutics Inc
CYCN
View Detailed Chart
1.460USD
-0.090-5.81%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
2.00MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.81%
5 Days
-8.18%
1 Month
+8.15%
6 Months
-37.61%
Year to Date
+14.96%
1 Year
-43.19%
View Detailed Chart
TradingKey Stock Score of Cyclerion Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Cyclerion Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 194 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cyclerion Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cyclerion Therapeutics Inc Highlights
StrengthsRisks
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 573.40% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.00M.
Fairly Valued
The company’s latest PE is -2.14, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 23.49K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
8.000
Target Price
+416.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cyclerion Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cyclerion Therapeutics Inc Info
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Ticker SymbolCYCN
CompanyCyclerion Therapeutics Inc
CEOGraul (Regina M)
Websitehttps://www.cyclerion.com/
Related Instruments
-1.16%
-0.37%
+1.36%
+5.68%
-0.69%
+0.95%
+0.45%
-1.22%
-0.40%
+0.67%
-2.98%
+0.25%
+0.57%
+0.60%
-2.33%
0.00%
-0.94%
-0.66%
-0.24%
+1.11%Popular Symbols
246.650
-6.240 (-2.47%)
165.060
-2.460 (-1.47%)
66621.400
+37.350 (+0.06%)
251.665
-21.685 (-7.93%)
2020.700
+20.700 (+1.03%)
355.270
-16.840 (-4.53%)
4510.780
+18.260 (+0.41%)
104.262
+3.653 (+3.63%)
1.146
-0.004 (-0.36%)
159.659
-0.593 (-0.37%)
